Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Glycine transporter 1 as a potential therapeutic target for schizophrenia-related symptoms: evidence from genetically modified mouse models and pharmacological inhibition.

Möhler H, Boison D, Singer P, Feldon J, Pauly-Evers M, Yee BK.

Biochem Pharmacol. 2011 May 1;81(9):1065-77. doi: 10.1016/j.bcp.2011.02.003. Epub 2011 Feb 17.

PMID:
21333635
[PubMed - indexed for MEDLINE]
2.

Altered mnemonic functions and resistance to N-METHYL-d-Aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1.

Singer P, Yee BK, Feldon J, Iwasato T, Itohara S, Grampp T, Prenosil G, Benke D, Möhler H, Boison D.

Neuroscience. 2009 Jun 30;161(2):635-54. doi: 10.1016/j.neuroscience.2009.03.056. Epub 2009 Mar 28.

PMID:
19332109
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

A novel glycine transporter-1 (GlyT1) inhibitor, ASP2535 (4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole), improves cognition in animal models of cognitive impairment in schizophrenia and Alzheimer's disease.

Harada K, Nakato K, Yarimizu J, Yamazaki M, Morita M, Takahashi S, Aota M, Saita K, Doihara H, Sato Y, Yamaji T, Ni K, Matsuoka N.

Eur J Pharmacol. 2012 Jun 15;685(1-3):59-69. doi: 10.1016/j.ejphar.2012.04.013. Epub 2012 Apr 20.

PMID:
22542656
[PubMed - indexed for MEDLINE]
4.

Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile.

Yee BK, Balic E, Singer P, Schwerdel C, Grampp T, Gabernet L, Knuesel I, Benke D, Feldon J, Mohler H, Boison D.

J Neurosci. 2006 Mar 22;26(12):3169-81.

PMID:
16554468
[PubMed - indexed for MEDLINE]
Free Article
5.

Intact working memory in the absence of forebrain neuronal glycine transporter 1.

Dubroqua S, Serrano L, Boison D, Feldon J, Gargiulo PA, Yee BK.

Behav Brain Res. 2012 Apr 21;230(1):208-14. doi: 10.1016/j.bbr.2012.01.061. Epub 2012 Feb 8.

PMID:
22342492
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Glycine reuptake inhibition as a new therapeutic approach in schizophrenia: focus on the glycine transporter 1 (GlyT1).

Chue P.

Curr Pharm Des. 2013;19(7):1311-20. Review.

PMID:
23194655
[PubMed - indexed for MEDLINE]
7.

Deletion of glycine transporter 1 (GlyT1) in forebrain neurons facilitates reversal learning: enhanced cognitive adaptability?

Singer P, Boison D, Möhler H, Feldon J, Yee BK.

Behav Neurosci. 2009 Oct;123(5):1012-27. doi: 10.1037/a0016676.

PMID:
19824767
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site.

Shim SS, Hammonds MD, Kee BS.

Eur Arch Psychiatry Clin Neurosci. 2008 Feb;258(1):16-27. Epub 2007 Sep 27. Review.

PMID:
17901997
[PubMed - indexed for MEDLINE]
9.

Rescue of hippocampal LTP and learning deficits in a rat model of psychosis by inhibition of glycine transporter-1 (GlyT1).

Manahan-Vaughan D, Wildförster V, Thomsen C.

Eur J Neurosci. 2008 Oct;28(7):1342-50. doi: 10.1111/j.1460-9568.2008.06433.x.

PMID:
18973561
[PubMed - indexed for MEDLINE]
10.

Pharmacological evaluation of a novel assay for detecting glycine transporter 1 inhibitors and their antipsychotic potential.

Alberati D, Moreau JL, Mory R, Pinard E, Wettstein JG.

Pharmacol Biochem Behav. 2010 Dec;97(2):185-91. doi: 10.1016/j.pbb.2010.07.016. Epub 2010 Aug 1.

PMID:
20678516
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Glycine transporter-1: a new potential therapeutic target for schizophrenia.

Hashimoto K.

Curr Pharm Des. 2011;17(2):112-20. Review.

PMID:
21355838
[PubMed - indexed for MEDLINE]
12.

Design of potent GlyT1 inhibitors: in vitro and in vivo profiles.

Bridges TM, Williams R, Lindsley CW.

Curr Opin Mol Ther. 2008 Dec;10(6):591-601. Review.

PMID:
19051137
[PubMed - indexed for MEDLINE]
13.

Inhibitors of GlyT1 affect glycine transport via discrete binding sites.

Mezler M, Hornberger W, Mueller R, Schmidt M, Amberg W, Braje W, Ochse M, Schoemaker H, Behl B.

Mol Pharmacol. 2008 Dec;74(6):1705-15. doi: 10.1124/mol.108.049312. Epub 2008 Sep 24. Erratum in: Mol Pharmacol. 2009 Jan;75(1):258.. Amberg, Martin Schmidt Willi [corrected to Schmidt, Martin]; Amberg, Martin Schmidt Willi [corrected to Amberg, Willi].

PMID:
18815213
[PubMed - indexed for MEDLINE]
Free Article
14.

Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia.

Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL Jr, Sur C, Kinney GG.

Curr Top Med Chem. 2006;6(8):771-85. Review.

PMID:
16719816
[PubMed - indexed for MEDLINE]
15.

Allosteric modulation of NMDA receptor via elevation of brain glycine and D-serine: the therapeutic potentials for schizophrenia.

Yang CR, Svensson KA.

Pharmacol Ther. 2008 Dec;120(3):317-32. doi: 10.1016/j.pharmthera.2008.08.004. Epub 2008 Aug 27. Review.

PMID:
18805436
[PubMed - indexed for MEDLINE]
16.

Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.

Depoortère R, Dargazanli G, Estenne-Bouhtou G, Coste A, Lanneau C, Desvignes C, Poncelet M, Heaulme M, Santucci V, Decobert M, Cudennec A, Voltz C, Boulay D, Terranova JP, Stemmelin J, Roger P, Marabout B, Sevrin M, Vigé X, Biton B, Steinberg R, Françon D, Alonso R, Avenet P, Oury-Donat F, Perrault G, Griebel G, George P, Soubrié P, Scatton B.

Neuropsychopharmacology. 2005 Nov;30(11):1963-85.

PMID:
15956994
[PubMed - indexed for MEDLINE]
Free Article
17.

The glycine transporter type 1 inhibitor N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl]sarcosine potentiates NMDA receptor-mediated responses in vivo and produces an antipsychotic profile in rodent behavior.

Kinney GG, Sur C, Burno M, Mallorga PJ, Williams JB, Figueroa DJ, Wittmann M, Lemaire W, Conn PJ.

J Neurosci. 2003 Aug 20;23(20):7586-91.

PMID:
12930797
[PubMed - indexed for MEDLINE]
Free Article
18.

Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification.

Javitt DC.

Curr Opin Drug Discov Devel. 2009 Jul;12(4):468-78. Review.

PMID:
19562643
[PubMed - indexed for MEDLINE]
19.

Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors.

Lindsley CW, Wolkenberg SE, Kinney GG.

Curr Top Med Chem. 2006;6(17):1883-96.

PMID:
17017963
[PubMed - indexed for MEDLINE]
20.

Glutamate-based therapeutic approaches: inhibitors of glycine transport.

Lechner SM.

Curr Opin Pharmacol. 2006 Feb;6(1):75-81. Epub 2005 Dec 22. Review.

PMID:
16376148
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk